Dr. Tefferi on the Toxicity Profile of Imetelstat

Video

In Partnership With:

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the toxicity of imetelstat in patients with myelofibrosis.

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the toxicity of imetelstat in patients with myelofibrosis.

Tefferi says there were few instances of non-hematologic toxicities when patients were given the drug every three weeks. Although clinicians were excited that there were no grade 3 or 4 toxicities, the drug has the ability to cause myelosuppression.

When patients were given imetelstat every three weeks, the incidence of grade 4 thrombocytopenia or neutropenia was below 10%, Tefferi says. However, when the drug was used every week, the incidence of grade 4 adverse events increased. Tefferi says that out of 11 patients who received weekly imetelstat, two of them developed severe myelosuppresion. Consequently, the weekly regimen was abandoned.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD